Replies to post #540 on Bionanao Genomics Inc (BNGO)

[BottomBounce]

$BNGO Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
Federated Kaufmann Fund 16,305 Mar 30, 2019 0.15% 71,089
Vanguard Extended Market Index Fund 9,790 Mar 30, 2019 0.09% 42,684
Victory Portfolios-Victory Munder Small Cap Growth Fund 8,136 Mar 30, 2019 0.07% 35,472
iShares Micro Cap ETF 4,881 Jul 30, 2019 0.04% 12,739
EQ Advisors Trust-1290 VT Micro Cap Port 750 Mar 30, 2019 0.01% 3,270
https://finance.yahoo.com/quote/BNGO/holders?p=BNGO&.tsrc=fin-srch

[BottomBounce]

$BNGO Professor from the Mayo Clinic used Saphyr to resolve challenging genomic regions implicated in neurodegenerative diseases on 31 brain samples collected post-mortem from patients with ALS, Parkinson’s disease, and Alzheimer’s disease. One of the causes of ALS is an expansion of a repeat in a gene called C9orf72. While no technology commonly used today for genome analysis has been capable of spanning and measuring the larger repeat expansions of this gene, Dr. Ebbert was able to use the Saphyr system to size a range of expansions from a single brain biopsy, demonstrating a full continuum of mosaicism. In patients with Parkinson’s disease, Saphyr resolved the structure of an inverted triplication of an associated gene. In patients with Alzheimer’s disease, Saphyr detected structural variants in CR1, an important gene with a repeat structure that cannot be fully analyzed with next-generation sequencing, and detected inversions in the Tau gene that protect against the disease. http://www.globenewswire.com/news-release/2019/10/24/1934941/0/en/Takeaways-from-ASHG-2019-in-Houston-Users-of-Bionano-s-Saphyr-System-Presented-Validation-Results-for-FSHD-Repeat-Expansion-Disorders-and-Digital-Cytogenetics-Among-a-Growing-List-.html